GeneOnline

What happens when you take a billion-year-old gene from a single-celled choanoflagellate and drop it into a mouse? A chimeric mouse—and a major shake-up in evolutionary biology! ?????? Scientists used this ancient gene to reprogram mouse cells into stem cells, proving that the roots of regenerative potential trace back to life’s earliest days. ??? This discovery redefines the history of stem cells and raises bold new possibilities for future medicine. ???? Are we rewriting the rules of nature??? Read more at ???? https://bit.ly/490twxA #StemCells #Evolution #Biotech #RegenerativeMedicine #EvolutionaryScience #BiotechInnovation #StemCellResearch #GeneticsBreakthrough

Let everyone wait for?the 9??th ! The 2025?9??th Asia Microbiome Conference, 50% off early bird tickets are officially launched! Be ready for Highlights of this conference?and watch it in one go! ? ?? 14 domestic and foreign academic and industry speakers gathered together ?? ?4 major themes: Human microorganisms and nutrition and probiotics, environmental microorganisms, marine microorganisms, creativity and venture capital ?? 100,000 Yuan Prize: Microbial Creativity Competition, boldly show off your "micro" creativity and meet you at the usual place #AcademiaSinica Humanities and Social Sciences Museum! ?? Want to have an in-depth understanding of foreign microbial testing service markets and operating models? ?? Keynote speech??? This year we are honored to invite Momchilo (Momo) Vuyisich, CSO and co-founder of Viome Life Sciences in the United States, as a Keynote Speaker and will join us online for the grand event. Viome is committed to using microbial technology to improve human health and has outstanding results in personalized health management and disease prevention. Dr. Vuyisich will bring forward-looking insights and inspire us to think new about the application of microorganisms. ?? More speech information?https://pse.is/5bn3m4? ?? 50% off early bird sale?https://pse.is/6lumm5 #亚洲microorganismtrendforum#AMC #50% off early bird

?? Is the Weight-Loss Market About to Explode? Eli Lilly and Company and Laekna Therapeutics just teamed up to tackle obesity with a drug aimed at weight loss WITHOUT muscle loss. ???♂??? With giants like Lilly and Novo Nordisk reigning supreme, new challengers—Regeneron, Scholar Rock, Roche, and Biohaven—are diving into the race. But here’s the kicker: Are these "miracle drugs" the future of health, or just fueling a billion-dollar obsession with weight? ???? ?? Where do you stand? Is this innovation or just another way big pharma cashes in on the weight-loss craze? Read more at ???? https://bit.ly/4fVdyav #ObesityCrisis #BigPharma #WeightLossDrugs #InnovationOrObsession

?? Antibody-Drug Conjugates (ADCs) Are Driving Innovation ?? ?? What are ADCs? ADCs combine monoclonal antibodies with chemotherapy drugs, delivering targeted therapies that attack cancer cells while sparing healthy tissue. This precision approach is transforming oncology treatments. ?? Market Insights: The global ADC market was valued at $10.8 billion in 2023 and is set to surge to $47 billion by 2029, growing at a staggering 28.4% CAGR! ??Breakthroughs in linker technologies and payload advancements are driving this growth, enhancing ADCs' efficacy and specificity. ?? Challenges Ahead: Managing adverse effects remains critical to ensuring patient safety and therapeutic success. Read more at ???? https://bit.ly/3V3d2zc #AntibodyDrugConjugates #CancerTreatment #PharmaInnovation #PrecisionMedicine #OncologyBreakthroughs #Biotech #Healthcare

From Taiwan Fungi to the Global Antimicrobial Market—The Journey of AMS BioteQ!??? Founded in 2018 by?Dr. George Tsai,?AMS BioteQ has leveraged Taiwan’s unique natural resources to focus on drug development and innovative medical materials. The company has successfully entered the global anti-infection market, transforming Taiwan’s distinctive fungi into potential new antibiotics and antiviral drugs, showcasing the power of biotech innovation!??? ?? Key Highlights: ?? Extracted?YUAN-01?and?YUAN-03?from Taiwan’s Antrodia camphorata, demonstrating exceptional inhibitory effects on drug-resistant bacteria like Staphylococcus aureus. ?? During the pandemic, AMS BioteQ collaborated with NTU College of Medicine and identified?YUAN-03?as significantly effective in inhibiting SARS-CoV-2 replication. ?? Developed?AMS-2140, which showed strong antiviral effects in animal studies, addressing diseases with no existing vaccines. ? ?? AMS BioteQ is dedicated to cross-industry innovation, not only developing new drugs but also introducing the Premium Vitality Drink ‘Chi’ for cancer patients undergoing chemotherapy and radiation, enhancing their quality of life and setting new standards in healthcare. ?? Read the full report here: ???? https://bit.ly/4eBHB5T ?? Follow GeneOnline to stay updated on the latest news on biotechnology and healthcare! ???? https://lnkd.in/dXtSXZ5u ?? Subscribe to the GeneOnline e-newsletter for weekly updates on biotechnology and healthcare! ???? https://bit.ly/486XjUU ____________________________ 從臺灣真菌到全球抗感染市場—元樟生技的創新之路！??? 由?蔡宜儒博士 於 2018 年創立的?元樟生技（AMS BioteQ），結合臺灣特有自然資源，專注於藥物開發與創新醫療材料研究。該公司成功進軍全球抗感染市場，將臺灣特色真菌轉化為抗菌與抗病毒的潛力新藥，彰顯生技創新的力量！?? ??關鍵亮點： ??從臺灣獨特的牛樟芝中提取?YUAN-01?和?YUAN-03，這些化合物在實驗中對藥物耐藥性細菌（如金黃色葡萄球菌）展現出色抑制效果。 ??疫情期間，元樟生技團隊與台大醫學院合作，發現?YUAN-03?對 SARS-CoV-2 的病毒複製具有顯著抑制作用。 ??開發出的?AMS-2140?在動物實驗中對登革病毒與禽流感病毒展現了強效抑制，為無疫苗疾病提供潛在治療選項。 ?? 元樟生技的跨產業合作：?公司致力於跨界合作，不僅研發創新藥物，還推出癌症病人營養飲品「元氣飲」，改善化療及放療患者的生活品質，為醫療照護注入新價值。 ??閱讀完整報導： ???? https://bit.ly/4fW9eYp ??追蹤基因線上，掌握生技醫療最新發展！ ???? https://geneonline.news/ ??訂閱基因線上電子報，接收每週生物技術和醫療保健的最新消息！ ???? https://bit.ly/3A8Yh6B

Are Psychedelics The Future of Mental Health or Big Pharma’s Nightmare??? ?? ?? Cybin Inc. just dropped groundbreaking 12-month Phase 2 data for CYB003, a proprietary deuterated psilocin drug targeting major depressive disorder (MDD).? ? The drug demonstrated unprecedented long-term efficacy, with sustained symptom remission for MDD patients.?? ? It received FDA Breakthrough Therapy Designation, fast-tracking its regulatory review due to its potential to outperform existing treatments.? ?? Are psychedelics the real future of mental health, or will Big Pharma push back??? ?? Could CYB003 disrupt the multibillion-dollar antidepressant market? ???? ?? Read more at ???? https://bit.ly/3V1JUs9 #Psychedelics #MentalHealth #Biotech #DepressionTreatment #FDA #PharmaInnovation #HealthcareRevolution??

$745M Bet: Novartis Takes on Radiopharma Giants!?? Novartis just struck a high-stakes deal with Ratio Therapeutics, potentially worth $745M, to develop a radiopharmaceutical targeting somatostatin receptor 2 (SSTR2) for cancer.?? ?? Here’s the breakdown: ? Ratio drives preclinical development. ? Novartis takes charge of development, manufacturing, and commercialization once a candidate is ready. This move sharpens Novartis’ edge in the booming radiopharmaceutical market, pitting them against fierce rivals like Bristol Myers Squibb and Eli Lilly and Company. With two approved radioligand therapies already under its belt, Novartis is clearly aiming for dominance. Read more at ???? https://bit.ly/3CA4dXn #CancerTreatment #Radiopharmaceuticals #BigPharma #Innovation #BiotechInvesting #HealthcareBreakthroughs

Insilico Medicine has achieved a major progress with its Phase IIa trial results for its AI-designed drug, ISM001-055, targeting idiopathic pulmonary fibrosis (IPF). ??? ?? Conducted across multiple sites in China, the trial revealed:?? ? Significant improvements in lung function ???? ? Dose-dependent efficacy ???? ? Excellent tolerability across all dosing regimens ??? This AI-powered innovation offers new hope for IPF patients and highlights the transformative potential of AI in drug discovery.? Read more at ???? https://x.gd/4YSt8 #AI #DrugDiscovery #IPF #Innovation #HealthcareTransformation #InsilicoMedicine

FDA Approves the World’s First Gene Therapy for AADC Deficiency: Kebilidi! ?? On November 14, 2024, the FDA officially approved?Kebilidi (Eladocagene Exuparvovec), the first gene therapy for?Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. This groundbreaking therapy uses adeno-associated viral vectors for one-time administration, restoring neurotransmitter production and offering life-changing solutions for patients! ?? ?? Key Highlights: ?? AADC deficiency, a rare metabolic genetic disorder, severely impacts motor functions and neurological development, posing life-threatening risks. Kebilidi introduces an effective new treatment for this condition. ?? Kebilidi delivers functional?DDC genes?into the brain’s substantia nigra and ventral tegmental areas, rebuilding dopamine and serotonin production, and significantly improving motor, behavioral, and autonomic functions. ?? Clinical trials show substantial improvements in motor functions, such as enhanced head control and assisted standing or walking. Symptoms like oculogyric crisis were significantly reduced or eliminated. ?? AADC deficiency is more prevalent in Asia, particularly in Taiwan with its specific gene mutations. Kebilidi’s approval is a milestone for treating patients in this region. ? ?? Read the full report here: ????https://lnkd.in/gRatgpXg ?? Follow GeneOnline to stay updated on the latest news on biotechnology and healthcare! ???? https://lnkd.in/dXtSXZ5u ?? Subscribe to the GeneOnline e-newsletter for weekly updates on biotechnology and healthcare! ????https://bit.ly/486XjUU -------------------------- FDA 核准全球首款 AADC 缺乏症基因療法——Kebilidi！??? 2024 年 11 月 14 日，美國食品藥物管理局（FDA）正式核准?Kebilidi（Eladocagene Exuparvovec），這是首款針對?芳香族 L-胺基酸脫羧酶（AADC）缺乏症?的基因療法。此藥物採用腺相關病毒載體技術，一次性注射即能恢復神經傳導物質生成功能，為患者帶來新型治療選擇！ ?? ?? 關鍵亮點： ?? AADC 缺乏症是一種罕見的代謝性遺傳疾病，影響患者運動功能、神經發展，甚至可能危及生命。Kebilidi 的出現為這類患者提供新型且有效的治療選擇。 ?? Kebilidi 透過注射含正常?DDC 基因?的病毒載體，精準傳導至腦部黑質與腹側被蓋區，恢復多巴胺和血清素的生成功能，臨床試驗顯示能有效改善運動、行為及自律神經異常問題。 ?? 臨床試驗顯示，患者接受治療後，運動功能大幅提升，如頭部控制增強，部分患者可輔助站立或行走，眼球危象等症狀明顯減少甚至消失。 ?? AADC 缺乏症在亞洲地區的盛行率較高，尤其是在台灣特定基因變異的發病率更為顯著。Kebilidi 的推出，對亞洲地區患者具有特別重要的治療價值。 ? ?? 閱讀完整報導： ????https://x.gd/cdnzl ?? 追蹤基因線上，掌握生技醫療最新發展！ ????https://geneonline.news/ ??訂閱基因線上電子報，接收每週生物技術和醫療保健的最新消息！ ????https://bit.ly/3A8Yh6B

Australia and Taiwan Join Forces to Advance Biotech Innovation at AusBiotech 2024!??? From October 28 to November 1,?AusBiotech 2024?lit up Melbourne with innovative insights and global collaboration in?clinical trials, biomedical manufacturing, and cell therapy. This event solidified the partnership between Taiwan and Australia, paving the way for healthcare innovation.???????? ??Highlights Recap: ??Led by BPIPO and DCB, the pavilion showcased Taiwan's innovations in?digital health, precision medicine, and immunotherapy, drawing significant attention. ??The delegation explored impactful research at?La Trobe University?and?Monash University, focusing on regenerative medicine and mRNA advancements. ?? Fostering Industry Ties: Engaged with premier clinical research organizations like?360biolabs, a BioAgilytix company?and?Nucleus Network, laying groundwork for future cross-border collaborations. ?? Creating a Shared Future: This event highlighted the complementary strengths of Australia and Taiwan in biotech innovation. The delegation brought home invaluable experiences, building bridges for stronger industry connections. ?? Read the full report here:? ???? https://bit.ly/3URlxNP ?? Follow GeneOnline to stay updated on the latest news on biotechnology and healthcare! ???? https://lnkd.in/dXtSXZ5u ?? Subscribe to the GeneOnline e-newsletter for weekly updates on biotechnology and healthcare! ???? https://bit.ly/3UQlmSQ Michael Huang Hsiu-Ling Tsui Ariel Lin Jackson TK Liu Cindy C. Jane Chiu Yi Yi Pei Hung Duli Chang Sam Huang Yu-Kuan (Tony) Huang Taipei Economic & Cultural Office Australian Trade and Investment Commission (Austrade) 向榮生技UnicoCell Biomed Development Center for Biotechnology Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) ACRO Biomedical Co., Ltd. KriSan Biotech Co., Ltd. AusBiotech Victorian Government Rosanne Hyland _______________________ 2024 澳洲生技大展：臺澳攜手創新，共建雙邊產業鏈新篇章！?? 10 月 28 日至 11 月 1 日，2024 年澳洲生技大展（AusBiotech 2024）?在墨爾本隆重舉行！來自全球的生技醫藥專家和產業領袖齊聚一堂，聚焦?臨床試驗、生醫製造與細胞療法?等重點領域，展現臺灣與澳洲攜手推動全球醫療創新的共識。???????? ??亮點回顧： ?? 臺灣館盛大揭幕：由 BPIPO 和 DCB 領軍，攜手臺灣生技企業展示在?數位健康、精準醫療與免疫療法?領域的創新成果，吸引眾多參觀者駐足。 ?? 參訪頂尖機構：代表團深入走訪?拉籌伯大學（La Trobe University）?和?蒙納許大學（Monash University）?等知名學術機構，探索再生醫學與 mRNA 技術等最新應用。 ?? 深化產業合作：與澳洲知名的?360biolabs?和?Nucleus Network?等臨床試驗機構進行交流，為未來跨國臨床合作鋪路。 ??臺澳共創生醫產學協作場域願景 本次大展充分彰顯澳洲與臺灣在生技創新與產業發展上的互補優勢。代表團收穫滿滿，不僅加深對?細胞療法與高端藥物製造?的了解，更為兩地的產業鏈聯結帶來嶄新契機。 ?? 查看留言區，閱讀完整報導? ???? https://bit.ly/40MQiau ?? 追蹤基因線上，掌握生技醫療最新發展 ???? https://geneonline.news/ ?? 訂閱基因線上電子報，接收每週生物技術和醫療保健的最新消息 ???? https://bit.ly/3A8Yh6B